Exploring the Correlation Between GPR176, a Potential Target Gene of Gastric Cancer, and Immune Cell Infiltration

References

• Nakagawa S, Nguyen Pham KT, Shao X, Doi M. Time-restricted g-protein signaling pathways via GPR176, Gz, and RGS16 set the pace of the master circadian clock in the suprachiasmatic nucleus. Int J Mol Sci. 2020;21(14):5055. doi:10.3390/ijms21145055
   PubMed Web of Science ®Google Scholar
• Yang D, Zhou Q, Labroska V, et al. G protein-coupled receptors: structure- and function-based drug discovery. Signal Transduct Target Ther. 2021;6(1):7. doi:10.1038/s41392-020-00435-w
   PubMed Web of Science ®Google Scholar
• Wang T, Nakagawa S, Miyake T, et al. Identification and functional characterisation of N-linked glycosylation of the orphan G protein-coupled receptor Gpr176. Sci Rep. 2020;10(1):4429. doi:10.1038/s41598-020-61370-y
   PubMed Web of Science ®Google Scholar
• Schultz DJ, Krishna A, Vittitow SL, et al. Transcriptomic response of breast cancer cells to anacardic acid. Sci Rep. 2018;8(1):8063. doi:10.1038/s41598-018-26429-x
   PubMedGoogle Scholar
• Doi M, Murai I, Kunisue S, et al. Gpr176 is a Gz-linked orphan G-protein-coupled receptor that sets the pace of circadian behaviour. Nat Commun. 2016;7(1):10583. doi:10.1038/ncomms10583
   PubMedGoogle Scholar
• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Xie J, Fu L, Jin L. Immunotherapy of gastric cancer: past, future perspective and challenges. Pathol Res Pract. 2021;218:153322. doi:10.1016/j.prp.2020.153322
   PubMed Web of Science ®Google Scholar
• Alkasalias T, Moyano-Galceran L, Arsenian-Henriksson M, Lehti K. Fibroblasts in the tumor microenvironment: shield or spear? Int J Mol Sci. 2018;19(5):1532. doi:10.3390/ijms19051532
   PubMed Web of Science ®Google Scholar
• Li W, Zhang X, Wu F, et al. Gastric cancer-derived mesenchymal stromal cells trigger M2 macrophage polarization that promotes metastasis and EMT in gastric cancer. Cell Death Dis. 2019;10(12):918. doi:10.1038/s41419-019-2131-y
   PubMedGoogle Scholar
• Wang H, Wu X, Chen Y. Stromal-immune score-based gene signature: a prognosis stratification tool in gastric cancer. Front Oncol. 2019;9:1212. doi:10.3389/fonc.2019.01212
   PubMed Web of Science ®Google Scholar
• Mantovani A, Romero P, Palucka AK, Marincola FM. Tumour immunity: effector response to tumour and role of the microenvironment. Lancet. 2008;371(9614):771–783. doi:10.1016/S0140-6736(08)60241-X
   PubMed Web of Science ®Google Scholar
• Fridman WH, Pages F, Sautes-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer. 2012;12(4):298–306. doi:10.1038/nrc3245
   PubMed Web of Science ®Google Scholar
• Liu F, Yang Z, Zheng L, et al. A tumor progression related 7-gene signature indicates prognosis and tumor immune characteristics of gastric cancer. Front Oncol. 2021;11:690129. doi:10.3389/fonc.2021.690129
   PubMed Web of Science ®Google Scholar
• Zappasodi R, Merghoub T, Wolchok JD. Emerging concepts for immune checkpoint blockade-based combination therapies. Cancer Cell. 2018;33(4):581–598. doi:10.1016/j.ccell.2018.03.005
   PubMed Web of Science ®Google Scholar
• Khasraw M, Reardon DA, Weller M, Sampson JH. PD-1 inhibitors: do they have a future in the treatment of glioblastoma? Clin Cancer Res. 2020;26(20):5287–5296. doi:10.1158/1078-0432.CCR-20-1135
   PubMed Web of Science ®Google Scholar
• Kono K, Nakajima S, Mimura K. Current status of immune checkpoint inhibitors for gastric cancer. Gastric Cancer. 2020;23(4):565–578. doi:10.1007/s10120-020-01090-4
   PubMed Web of Science ®Google Scholar
• Tomczak K, Czerwinska P, Wiznerowicz M. The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge. Contemp Oncol. 2015;19(1A):A68–A77.
   Google Scholar
• Blum A, Wang P, Zenklusen JC. SnapShot: TCGA-analyzed tumors. Cell. 2018;173(2):530. doi:10.1016/j.cell.2018.03.059
   PubMed Web of Science ®Google Scholar
• Goldman MJ, Craft B, Hastie M, et al. Visualizing and interpreting cancer genomics data via the xena platform. Nat Biotechnol. 2020;38(6):675–678. doi:10.1038/s41587-020-0546-8
   PubMed Web of Science ®Google Scholar
• Clough E, Barrett T. The gene expression omnibus database. Methods Mol Biol. 2016;1418:93–110.
   PubMedGoogle Scholar
• Chan BKC. Data Analysis Using R Programming. Adv Exp Med Biol. 2018;1082:47–122.
   PubMed Web of Science ®Google Scholar
• Li Y, Bian Y, Wang K, Wan XP. POLE mutations improve the prognosis of endometrial cancer via regulating cellular metabolism through AMF/AMFR signal transduction. BMC Med Genet. 2019;20(1):202. doi:10.1186/s12881-019-0936-2
   PubMed Web of Science ®Google Scholar
• Mayakonda A, Lin DC, Assenov Y, Plass C, Koeffler HP. Maftools: efficient and comprehensive analysis of somatic variants in cancer. Genome Res. 2018;28(11):1747–1756. doi:10.1101/gr.239244.118
   PubMed Web of Science ®Google Scholar
• Liu TT, Li R, Huo C, et al. Identification of CDK2-related immune forecast model and ceRNA in lung adenocarcinoma, a pan-cancer analysis. Front Cell Dev Biol. 2021;9:682002. doi:10.3389/fcell.2021.682002
   PubMed Web of Science ®Google Scholar
• Mehdi T, Bailey SD, Guilhamon P, Lupien M, Kelso J. C3D: a tool to predict 3D genomic interactions between cis-regulatory elements. Bioinformatics. 2019;35(5):877–879. doi:10.1093/bioinformatics/bty717
   PubMed Web of Science ®Google Scholar
• Chen B, Khodadoust MS, Liu CL, Newman AM, Alizadeh AA. Profiling tumor infiltrating immune cells with CIBERSORT. Methods Mol Biol. 2018;1711:243–259.
   PubMedGoogle Scholar
• Li T, Fu J, Zeng Z, et al. TIMER2.0 for analysis of tumor-infiltrating immune cells. Nucleic Acids Res. 2020;48(W1):W509–W514. doi:10.1093/nar/gkaa407
   PubMed Web of Science ®Google Scholar
• Giorgi FM, Ceraolo C, Mercatelli D. The R language: an engine for bioinformatics and data science. Life. 2022;12(5):648. doi:10.3390/life12050648
   PubMedGoogle Scholar
• Powers RK, Goodspeed A, Pielke-Lombardo H, Tan AC, Costello JC. GSEA-InContext: identifying novel and common patterns in expression experiments. Bioinformatics. 2018;34(13):i555–i564. doi:10.1093/bioinformatics/bty271
   PubMed Web of Science ®Google Scholar
• Suwazono S, Arao H. A newly developed free software tool set for averaging electroencephalogram implemented in the Perl programming language. Heliyon. 2020;6(11):e05580. doi:10.1016/j.heliyon.2020.e05580
   PubMed Web of Science ®Google Scholar
• Digre A, Lindskog C. The human protein atlas-spatial localization of the human proteome in health and disease. Protein Sci. 2021;30(1):218–233. doi:10.1002/pro.3987
   PubMed Web of Science ®Google Scholar
• Wu J, Li L, Zhang H, et al. A risk model developed based on tumor microenvironment predicts overall survival and associates with tumor immunity of patients with lung adenocarcinoma. Oncogene. 2021;40(26):4413–4424. doi:10.1038/s41388-021-01853-y
   PubMed Web of Science ®Google Scholar
• Li T, Fan J, Wang B, et al. TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells. Cancer Res. 2017;77(21):e108–e110. doi:10.1158/0008-5472.CAN-17-0307
   PubMed Web of Science ®Google Scholar
• Aran D, Hu Z, Butte AJ. xCell: digitally portraying the tissue cellular heterogeneity landscape. Genome Biol. 2017;18(1):220. doi:10.1186/s13059-017-1349-1
   PubMed Web of Science ®Google Scholar
• Zheng H, Liu H, Ge Y, Wang X. Integrated single-cell and bulk RNA sequencing analysis identifies a cancer associated fibroblast-related signature for predicting prognosis and therapeutic responses in colorectal cancer. Cancer Cell Int. 2021;21(1):552. doi:10.1186/s12935-021-02252-9
   PubMed Web of Science ®Google Scholar
• Gajewski TF, Corrales L, Williams J, Horton B, Sivan A, Spranger S. Cancer immunotherapy targets based on understanding the T cell-inflamed versus non-T cell-inflamed tumor microenvironment. Adv Exp Med Biol. 2017;1036:19–31.
   PubMed Web of Science ®Google Scholar
• Garris CS, Luke JJ. Dendritic cells, the T-cell-inflamed tumor microenvironment, and immunotherapy treatment response. Clin Cancer Res. 2020;26(15):3901–3907. doi:10.1158/1078-0432.CCR-19-1321
   PubMed Web of Science ®Google Scholar
• Fu J, Li K, Zhang W, et al. Large-scale public data reuse to model immunotherapy response and resistance. Genome Med. 2020;12(1):21. doi:10.1186/s13073-020-0721-z
   PubMed Web of Science ®Google Scholar
• Prior FW, Clark K, Commean P, et al. TCIA: an information resource to enable open science. Annu Int Conf IEEE Eng Med Biol Soc. 2013;2013:1282–1285. doi:10.1109/EMBC.2013.6609742
   PubMedGoogle Scholar
• Zeng Z, Ma C, Chen K, et al. Roles of G Protein-Coupled Receptors (GPCRs) in gastrointestinal cancers: focus on sphingosine 1-shosphate receptors, angiotensin ii receptors, and estrogen-related GPCRs. Cells. 2021;10(11). doi:10.3390/cells10112988
   Web of Science ®Google Scholar
• Goto K, Doi M, Wang T, Kunisue S, Murai I, Okamura H. G-protein-coupled receptor signaling through Gpr176, Gz, and RGS16 tunes time in the center of the circadian clock [Review]. Endocr J. 2017;64(6):571–579. doi:10.1507/endocrj.EJ17-0130
   PubMed Web of Science ®Google Scholar
• Dorsam RT, Gutkind JS. G-protein-coupled receptors and cancer. Nat Rev Cancer. 2007;7(2):79–94. doi:10.1038/nrc2069
   PubMed Web of Science ®Google Scholar
• Liu Y, An S, Ward R, et al. G protein-coupled receptors as promising cancer targets. Cancer Lett. 2016;376(2):226–239. doi:10.1016/j.canlet.2016.03.031
   PubMed Web of Science ®Google Scholar
• Ribeiro-Oliveira R, Vojtek M, Goncalves-Monteiro S, et al. Nuclear G-protein-coupled receptors as putative novel pharmacological targets. Drug Discov Today. 2019;24(11):2192–2201. doi:10.1016/j.drudis.2019.09.003
   PubMed Web of Science ®Google Scholar
• Schoneberg T, Schulz A, Biebermann H, Hermsdorf T, Rompler H, Sangkuhl K. Mutant G-protein-coupled receptors as a cause of human diseases. Pharmacol Ther. 2004;104(3):173–206. doi:10.1016/j.pharmthera.2004.08.008
   PubMed Web of Science ®Google Scholar
• Lawal B, Lin LC, Lee JC, et al. Multi-omics data analysis of gene expressions and alterations, cancer-associated fibroblast and immune infiltrations, reveals the onco-immune prognostic relevance of STAT3/CDK2/4/6 in human malignancies. Cancers. 2021;13(5):954. doi:10.3390/cancers13050954
   PubMed Web of Science ®Google Scholar
• Vinay DS, Ryan EP, Pawelec G, et al. Immune evasion in cancer: mechanistic basis and therapeutic strategies. Semin Cancer Biol. 2015;35(Suppl):S185–S198. doi:10.1016/j.semcancer.2015.03.004
   PubMed Web of Science ®Google Scholar
• Jhunjhunwala S, Hammer C, Delamarre L. Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion. Nat Rev Cancer. 2021;21(5):298–312. doi:10.1038/s41568-021-00339-z
   PubMed Web of Science ®Google Scholar
• Kaderbhai C, Tharin Z, Ghiringhelli F. The role of molecular profiling to predict the response to immune checkpoint inhibitors in lung cancer. Cancers. 2019;11(2):201. doi:10.3390/cancers11020201
   PubMed Web of Science ®Google Scholar
• Sanmamed MF, Chen L. A paradigm shift in cancer immunotherapy: from enhancement to normalization. Cell. 2018;175(2):313–326. doi:10.1016/j.cell.2018.09.035
   PubMed Web of Science ®Google Scholar